Product image of Modopar 125 Dispersible (Benserazide Hydrochloride, Levodopa) supplied by GNH India

Modopar 125 Dispersible

Active Ingredient:
Benserazide Hydrochloride, Levodopa
Origin:
EU

Modopar 125 Dispersible (Benserazide Hydrochloride, Levodopa)

Levodopa, the active ingredient in Modopar 125 Dispersible, is a dopamine precursor presented as a Levodopa 100 mg / Benserazide Hydrochloride 25 mg dispersible tablet for oral use. It treats Parkinson's disease by restoring central dopamine levels in patients with motor symptoms.

GNH India supplies Modopar 125 Dispersible as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and other markets. Our distribution network ensures timely delivery and supports local import requirements.

Manufacturer / TM Owner

Roche

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Modopar 125 Dispersible combines levodopa and benserazide to address the dopaminergic deficit in Parkinson's disease. It is used for:

  • Parkinson's disease (early stage): improves motor function and reduces rigidity.
  • Parkinson's disease with motor fluctuations: smooths out on‑off periods.
  • Parkinson's disease with dyskinesia: helps balance dopamine levels and lessen involuntary movements.

How It Works

  • Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine within the central nervous system, replenishing depleted dopamine stores. Benserazide, a peripheral aromatic L‑amino acid decarboxylase inhibitor, blocks levodopa conversion outside the brain, increasing the amount of levodopa that reaches the CNS and enhancing its therapeutic effect.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Dizziness: sensation of light‑headedness, especially when standing.
  • Headache: transient cranial discomfort.
  • Orthostatic hypotension: drop in blood pressure upon standing.
  • Insomnia: difficulty initiating or maintaining sleep.
  • Constipation: reduced bowel motility.

Serious or Rare Side Effects

  • Hallucinations: visual or auditory disturbances.
  • Severe hypotension: marked drop in blood pressure requiring medical attention.
  • Dyskinesia: involuntary, erratic movements.
  • Cardiac arrhythmias: irregular heart rhythms.
  • Neuroleptic malignant syndrome: rare, life‑threatening reaction.
  • Severe allergic reactions: rash, swelling, or breathing difficulty.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Dose titration: start low and increase gradually as directed by the prescriber.
  • Monitor blood pressure: watch for orthostatic hypotension, especially in the elderly.
  • Assess renal/hepatic function: adjust dosing if significant impairment is present.
  • Avoid abrupt discontinuation: sudden stop may worsen Parkinsonian symptoms.
  • Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Modopar 125 Dispersible may interact with several medicines.

Major Interactions (Avoid)

  • MAO‑B inhibitors: risk of hypertensive crisis.
  • Non‑selective MAO inhibitors: can cause severe hypertension.
  • Antipsychotics (e.g., haloperidol): may reduce levodopa efficacy.
  • Anticholinergics: may increase central side effects.

Moderate Interactions (Monitor Closely)

  • Iron supplements: decrease levodopa absorption; separate dosing by at least 2 hours.
  • High‑protein meals: may reduce levodopa uptake from the gut.
  • SSRIs/SNRIs: potential for serotonin syndrome when combined with MAO inhibitors.

Frequently Asked Questions

Modopar 125 Dispersible is prescribed to manage the motor symptoms of Parkinson's disease. It combines levodopa, which replenishes brain dopamine, with benserazide, which prevents peripheral conversion of levodopa, thereby enhancing its effectiveness in improving movement control.

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier and is converted into dopamine within the central nervous system. This increase in dopamine helps compensate for the loss of dopaminergic neurons characteristic of Parkinson's disease, improving motor function.

The specific dose of Modopar 125 Dispersible is determined by the prescribing clinician based on the individual’s disease stage, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Modopar 125 Dispersible in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Modopar 125 Dispersible combines levodopa with benserazide, offering a balanced approach that maximizes central dopamine delivery while limiting peripheral side effects. Compared with levodopa alone, the combination often provides more consistent symptom control and may reduce the required levodopa dose.

Store Modopar 125 Dispersible at temperatures below 25 °C in its original packaging. Protect the tablets from moisture and direct sunlight to maintain stability and potency throughout the shelf life.

The dispersible tablet should be placed in a small amount of water, allowed to dissolve completely, and then ingested orally. It can be taken with or without food, but consistent timing relative to meals helps maintain stable drug absorption.

Serious risks include severe hypotension, hallucinations, dyskinesia, and rare but life‑threatening conditions such as neuroleptic malignant syndrome. Patients should be monitored closely for these events, and any sudden changes in blood pressure, mental status, or involuntary movements should be reported promptly.

Modopar 125 Dispersible is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, as it may exacerbate the condition.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Benserazide Hydrochloride, Levodopa

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT